Comparative Pharmacology
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus UCERIS.
Peer-Reviewed Evidence
Head-to-head clinical analysis: FLOVENT DISKUS 250 versus UCERIS.
FLOVENT DISKUS 250 vs UCERIS
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Fluticasone propionate is a corticosteroid with potent anti-inflammatory activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines, reduction of eosinophil recruitment, and suppression of airway hyperresponsiveness.
Uceris (budesonide) is a corticosteroid with potent glucocorticoid activity. It binds to the glucocorticoid receptor, leading to inhibition of pro-inflammatory cytokines (e.g., IL-1, IL-2, IL-4, IL-5, TNF-alpha), suppression of arachidonic acid metabolism via phospholipase A2 inhibition, and reduction of inflammatory cell infiltration. It has high topical anti-inflammatory activity and undergoes extensive first-pass hepatic metabolism, minimizing systemic bioavailability.
250 mcg inhaled orally via DISKUS twice daily (500 mcg total daily dose).
For induction of remission in mild to moderate active ulcerative colitis: one 9 mg extended-release tablet orally once daily for up to 8 weeks.
None Documented
None Documented
Approximately 10-12 hours (terminal elimination half-life in asthmatics).
2.8-4.5 hours (terminal). Clinical context: short half-life supports once-daily extended-release formulation for colonic delivery.
Renal (approximately 5% as unchanged drug); fecal (majority as metabolites and unabsorbed drug).
Renal: <1%. Fecal: approximately 63% as budesonide and metabolites. Biliary: minor.
Category C
Category C
Corticosteroid
Corticosteroid